FBXO32 and cardiac hypertrophy: Furthermore, the silencing USP19 inhibits denervation‐ or glucocorticoid‐induced muscle atrophy by suppressing protein degradation, with a notably decreased expression of the ubiquitin ligases MuRF1 and MAFbx/atrogin‐1,12 which are correlated to the cardiac hypertrophy blockade.15, 16